Organon & Co. (NYSE: OGN) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $3.7B. The Maz Rating grades it against the other companies in its sector.
Organon & Co.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.90, Organon & Co. trades at 17.6x trailing earnings, 0.6x sales and 3.1x book value, with an EV/EBITDA of 8.3. Over the last twelve months it generated about $6.1B of revenue and $207M of net income. It runs a gross margin of 53.4%, an operating margin of 19.5% and a net margin of 3.5%. It shows return on equity of 22.1%, return on invested capital of 4.7% and a free cash flow yield of 18.5%. On the balance sheet: a debt-to-equity ratio of 7.17 and a current ratio of 2.02. Over the past 52 weeks the share price ranged from $5.69 to $13.91, with a beta of 1.52.
Organon & Co. pays a dividend yielding 0.58%, with 9% of earnings paid out. Its Maz Dividend Score is 2.50 out of 5, ranked against the other dividend payers in its sector (Safety 3.97, Growth 1.77, Yield 3.43, Consistency 1.10).
9 Wall Street analyst ratings cover the stock: 2 Buy, 4 Hold and 3 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Organon & Co. (OGN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 236.7% / 30% · (Cash+Inv) / Mkt Cap (36m) 40.3% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 236.7% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 40.3% / 33% · Receivables / Mkt Cap (36m) 41.0% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 236.7% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 40.3% / 33.33% · Receivables / Mkt Cap (24m) 41.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 65.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 8.16% / 33.33% · Receivables / Avg Assets (4Q) 11.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 63.8% / 33.33% · (Cash+ST Inv) / Total Assets 10.9% / 33.33% · (Cash+Recv) / Total Assets 21.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Organon & Co. (OGN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Organon & Co. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
Organon & Co. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.